Plasma protein biomarkers of Plasmodium falciparum infection in pregnant women: a high-throughput proteomics study
Frontiers in Cellular and Infection Microbiology · 2025
DOI: 10.3389/fcimb.2025.1594088 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2025. Verfasst von Bernard N Kanoi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Malaria Elimination, Institute of Tropical Medicine, Mount Kenya University, Thika, Kenya. Hauptthemen laut MEDLINE: Malaria, Falciparum, Biomarkers, Pregnancy Complications, Parasitic, Blood Proteins. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Pregnant women in sub-Saharan Africa face heightened susceptibility to Plasmodium falciparum malaria, with placental sequestration driving adverse outcomes. The infection may lead to pregnancy-associated malaria (PAM) because of the sequestration of Plasmodium falciparum -infected erythrocytes in the placental intervillous space. Although there are several tools for diagnosing malaria infection during pregnancy, including blood smear microscopic examination, rapid diagnostic tests, and PCR, there are no tools for detecting placental infection and, by extension, any dysfunction associated with PAM. Thus, PAM, specifically placental infection, can only be confirmed via postnatal placental histopathology. Therefore, there is an urgent need for specific plasma biomarkers of PAM.
Methods
Here, we used the high throughput proximity extension assay to screen plasma from malaria-exposed pregnant women for differentially expressed proteins that may serve as candidate biomarkers of Plasmodium falciparum infection during pregnancy, with future potential to inform diagnosis of PAM or adverse malaria outcomes. Such biomarkers may also elucidate the pathophysiology of PAM.
Results
Using proximity extension assay (PEA), we identified elevated IgG Fc receptor IIb (FCGR2B) and heme oxygenase-1 (HO-1) in malaria-positive pregnancies, while neurturin (NRTN) and IL-20 were downregulated.
Discussion
IL-20 emerged as a top candidate biomarker, warranting validation in large cohorts with placental histopathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Malaria Elimination, Institute of Tropical Medicine, Mount Kenya University, Thika, Kenya.
- School of Public Health, Mount Kenya University, Thika, Kenya.
- School of Pure and Applied Sciences, Mount Kenya University, Thika, Kenya.
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
- Department of Medical Sciences, Clinical Chemistry and SciLifeLab Affinity Proteomics, Uppsala University, Uppsala, Sweden.
- Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, United Kingdom.
Zitieren
APA
Kanoi, B. N., Waweru, H., Kobia, F. M., Mukala, J., Kirira, P., Mogere, D., Gallini, R., Åberg, M., Vatish, M., Gitaka, J., & Kamali-Moghaddam, M. (2025). Plasma protein biomarkers of Plasmodium falciparum infection in pregnant women: a high-throughput proteomics study. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1594088
Vancouver
Kanoi BN, Waweru H, Kobia FM, Mukala J, Kirira P, Mogere D, et al. Plasma protein biomarkers of Plasmodium falciparum infection in pregnant women: a high-throughput proteomics study. Frontiers in Cellular and Infection Microbiology. 2025. doi:10.3389/fcimb.2025.1594088
BibTeX
@article{Kanoi2025,
author = {Kanoi, Bernard N and Waweru, Harrison and Kobia, Francis M and Mukala, Joseph and Kirira, Peter and Mogere, Dominic and Gallini, Radiosa and Åberg, Mikael and Vatish, Manu and Gitaka, Jesse and Kamali-Moghaddam, Masood},
title = {Plasma protein biomarkers of Plasmodium falciparum infection in pregnant women: a high-throughput proteomics study},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2025},
doi = {10.3389/fcimb.2025.1594088}
}
EUVIMED